-
Mashup Score: 55Improving Outcomes for Early-Stage NSCLC Using Targeted Therapy - 21 day(s) ago
Current research efforts in early-stage NSCLC have expanded to explore the efficacy of targeted therapy in patients with oncogenic driver mutations beyond EGFR and ALK.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 14
The guideline provides recommendations to clinicians for discussing cannabis and cannabinoid use with patients, as well as where the evidence supports their use.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Medicinal use of cannabis/cannabinoids has outpaced clinical research; to fill this information void, a new guideline provides recommendations to clinicians for discussions w/ pts + where evidence supports their use: https://t.co/6xUqPQkdrL #ASCODailyNews @MDRoeland @DrIlanaBraun https://t.co/VirHVtamfl
-
-
Mashup Score: 17Implementing Policy- and System-Level Interventions to Address Rural Health Disparities in Patients With Cancer - 3 month(s) ago
Disparities in cancer outcomes, including a heightened risk of adverse cancer outcomes, are prevalent among rural populations. Authors discuss policy and system interventions to implement change and improve health equity.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Patients in rural areas experience a higher risk of adverse cancer outcomes for a variety of reasons. @JoshNHerb, @ColonCancerDoc & Dr. Rebecca Snyder discuss opportunities to improve care & implement systemic change: https://t.co/Ob4I0BWg58 @MDAndersonNews #ASCODailyNews https://t.co/tPIsBK4bDD
-
-
Mashup Score: 14Choosing the Right Test for the Right Patient at the Right Time: Establishing Guidelines for Molecular Panels in Sarcomas - 6 month(s) ago
Commercially available platforms in the management of sarcomas are expanding in terms of the technology used, breadth of coverage, depth of coverage, specimen assayed, and gene lists tested. Thus, it is a critical time to ask the question: Is it time to provide guidelines on how to select a comprehensive panel based on the tumor type?
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
I was happy to write with my colleague @candace_haddox this opinion piece about the need of a consensus for the use of molecular panels in sarcomas. Thank you @asco and #ascodailynews ! https://t.co/ziFnabOIzw
-
-
Mashup Score: 1
Drs. Diwakar Davar and Benjamin Boursi discuss the role of the gut microbiome in the outcome of cancer immunotherapy and the prevention of immunotherapy-related adverse events, as well as compelling research on nutritional interventions to improve response to immune checkpoint inhibitors.
Source: dailynews.ascopubs.orgCategories: Latest Headlines, Partners & KOLsTweet-
🎙️ @diwakardavar of @UPMCHillmanCC and Dr. Ben Boursi of @sheba_medical discuss the role of the gut microbiome in the outcome of cancer immunotherapy on the #ASCODailyNews Podcast: https://t.co/1VP90hS1OK #ASCODailyNews https://t.co/YAjVNTty4S
-
-
Mashup Score: 1Should Induction Chemoimmunotherapy Lead Us to Broaden Our Definition of Resectability in NSCLC? - 7 month(s) ago
Dr. Howard (Jack) West explores the question of whether the prevailing standard of care in resectable NSCLC should change so that surgery becomes the routine recommendation for patients beyond the upper limit of what has historically been considered as surgical disease.
Source: dailynews.ascopubs.orgCategories: Latest Headlines, Partners & KOLsTweet-
Should induction #chemoimmunotherapy lead us to broaden our definition of resectability in #NSCLC? @JackWestMD provides his insights in the latest #ASCODailyNews editorial: https://t.co/LFVPcxyb6I #lungcancer #lcsm https://t.co/FMlmrdLAH5
-
-
Mashup Score: 0Nutrition and Exercise Screening Is Essential to Whole-Body Cancer Care, But Implementation Challenges Remain - 7 month(s) ago
Timely exercise and nutrition screening and prompt referrals are essential to treat patients needing lifestyle modifications after a cancer diagnosis. The integrative oncology framework can provide comprehensive, team-based support.
Source: dailynews.ascopubs.orgCategories: Latest Headlines, Partners & KOLsTweet-
Experts from @MDAndersonNews explore recommendations on the role of diet & exercise during a cancer diagnosis and the importance of screening to identify nutrition and physical activity status in pts. Read more: https://t.co/GwqAM91i9h #ASCODailyNews #supponc #pallonc #exonc https://t.co/hLi91leRnj
-
-
Mashup Score: 5Podcast: Navigating the Complexities of Next-Generation Endocrine Therapy in HR+ Breast Cancer - 7 month(s) ago
Drs. Hope Rugo and Nancy Davidson discuss the next generation of endocrine therapy in hormone receptor-positive breast cancer – SERDs, SERMs, CERANs, and PROTACs – and challenges relating to the optimal sequence of therapeutic options.
Source: dailynews.ascopubs.orgCategories: Latest Headlines, Partners & KOLsTweet-
.@hoperugo of @UCSFCancer & Dr. Nancy Davidson of @fredhutch discuss next-gen endocrine therapies in HR+ #BreastCancer and the optimal sequence of therapies on the #ASCODailyNews Podcast. https://t.co/RggxEE27Q2 #bcsm https://t.co/xiY61kk61j
-
-
Mashup Score: 2HERTHENA-Lung-01 Demonstrates Activity with Patritumab Deruxtecan in Patients With Previously Treated EGFR-Mutated NSCLC - 8 month(s) ago
The HER3-targeting antibody-drug conjugate patritumab deruxtecan appears to be active in patients with EGFR-mutated NSCLC previously treated with an EGFR TKI and platinum-based chemotherapy, with a confirmed ORR of 29.8%.
Source: dailynews.ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New #JCO research presented at #WCLC23: Patritumab deruxtecan appears to be active in pts w/ EGFR-mutated #NSCLC previously treated with an EGFR TKI & platinum-based chemotherapy, w/ a confirmed ORR of 29.8%. Read more in #ASCODailyNews: https://t.co/gzalYdtPfW #lcsm https://t.co/mimLkONDf5
-
-
Mashup Score: 0Patient-Reported Outcomes: Are All Patients Equally Engaged? - 8 month(s) ago
Considering the significant barriers to obtaining accurate and reliable data, investigators should use caution when using PROs to compare groups of different socioeconomic, ethnic, and racial backgrounds, as poor data may lead to erroneous conclusions.
Source: dailynews.ascopubs.orgCategories: Latest Headlines, Partners & KOLsTweet-
PROs: Are all patients equally engaged? @laura_tennerMD & @AparGanti explore current studies that have shown there are differences in PRO results between pts of different backgrounds & discuss solutions. https://t.co/SYQn83NfuG #ASCODailyNews #healthequity https://t.co/zaCCGnJwyh
-
Check out our article featured in #ASCOdailyNews "Improving Outcomes for Early-Stage NSCLC Using Targeted Therapy" A big shout-out to Dr. Vanya Aggarwal, a second-year fellow at @LombardiCancer, for her great work @ASCO Link: https://t.co/8vemjuhdz6 https://t.co/VNPyil8Cjb